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Abstract
Introduction: Lifelong antiretroviral therapy (ART) improves health outcomes for HIV-positive individuals, but is jeopardized
by irregular clinic attendance and hence poor adherence. Loss to follow-up (LTFU) is typically defined retrospectively but this
may lead to biased inferences. We assessed incidence of and factors associated with LTFU, prospectively and accounting for
recurrent LTFU episodes, in the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) of HIV-positive persons in rural
Tanzania.
Methods: We included adults (≥15 years) enrolled in 2005 to 2016, regardless of ART status, with follow-up through April
2017. LTFU was defined as >60 days late for a scheduled appointment. Participants could experience multiple LTFU episodes.
We performed analyses based on the first (prospective) and last (retrospective) events observed during follow-up, and
accounting for recurrent LTFU episodes. Time to LTFU was estimated using cumulative incidence functions. We assessed fac-
tors associated with LTFU using cause-specific proportional hazards, marginal means/rates, and Prentice, Williams and Peter-
son models.
Results: Among 8087 participants (65% female, 60% aged ≥35 years, 42% WHO stage 3/4, and 47% CD4 count <200 cells/
mm3), there were 8140 LTFU episodes, after which there were 2483 (31%) returns to care. One-year LTFU probabilities were
0.41 (95% confidence interval 0.40, 0.42) and 0.21 (0.20, 0.22) considering the first and last events respectively. Factors asso-
ciated with LTFU were broadly consistent across different models: being male, younger age, never married, living far from the
clinic, not having an HIV-positive partner, lower BMI, advanced WHO stage, not having tuberculosis, and shorter time since
ART initiation. Associations between LTFU and pregnancy, CD4 count, and enrolment year depended on the analysis approach.
Conclusions: LTFU episodes were common and prompt tracing efforts are urgently needed. We identified socio-demographic
and clinical characteristics associated with LTFU that can be used to target tracing efforts and to help inform the design of
appropriate interventions. Incidence of and risk factors for LTFU differed based on the LTFU definition applied, highlighting
the importance of appropriately accounting for recurrent LTFU episodes. We recommend using a prospective definition of
LTFU combined with recurrent event analyses in cohorts where repeated interruptions in care are common.
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1 | INTRODUCTION
Lifelong antiretroviral therapy (ART) is crucial to optimize
health outcomes for people living with HIV [1]. Retention in
care is a critical component to reaching the second and third
UNAIDS 90-90-90 targets, that is, that 90% of HIV-positive
persons are on ART, and 90% of those have suppressed viral
load [2]. In 2012, loss to follow-up (LTFU) was declared as
one of the key challenges for the next decade facing HIV
care and treatment programmes in resource-limited settings
[3]. LTFU from such programmes occurs at all steps of the
care cascade, from diagnosis, during ART eligibility
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assessment, and after ART initiation [4–6]. Irregular clinic
attendance and poor ART adherence increase the risks of
drug resistance, morbidity, mortality and HIV transmission
[4,5,7,8].
The risk of LTFU varies between HIV programmes, with
estimates ranging from 0.3% to 50% [9], partly due to differ-
ent time periods being considered. Furthermore, the defini-
tion of LTFU is not standardised and can have a large
impact on estimates [10]. The definition of LTFU should be
constructed appropriately based on the research question of
interest [11]. Retrospective or “last event” definitions of
LTFU – i.e. based on whether an individual was considered
to be in care at the time of database closure – may lead to
biased estimates for LTFU trends due to transient interrup-
tions in care [11]. Prospective or “first event” definitions of
LTFU – that is based on first interruptions in care – are
therefore preferable. Alternatively, recurrent interruptions in
care could be assessed directly, thus making more efficient
use of the data [12].
Previous studies have identified the factors associated with
LTFU among persons on ART to include younger age, male
sex, single, divorced or separated marital status, illiteracy, hav-
ing no income-generating occupation, non-disclosure of HIV
diagnosis, stigma, distance to health facilities, poor nutrition,
normal body mass index, pregnancy, high or low CD4 count,
tuberculosis co-infection, advanced clinical staging, detectable
viral load and adverse drug reactions [5,8,9,13–21]. However,
most of these studies employed retrospective LTFU defini-
tions; to our knowledge, no studies have assessed factors
associated with recurrent LTFU episodes from HIV pro-
grammes.
Our objectives were to identify the incidence of and factors
associated with LTFU among HIV-positive adults (regardless
of ART status) enrolled in the Kilombero and Ulanga
Antiretroviral Cohort (KIULARCO) in a rural HIV clinic in Ifa-
kara, Morogoro, Tanzania, prospectively and appropriately
accounting for recurrent LTFU episodes.
2 | METHODS
2.1 | Study site, population and study design
The Chronic Disease Clinic of Ifakara (CDCI) is a rural HIV
care and treatment centre established in 2004, operating
under Saint Francis Referral Hospital and serving people living
with HIV from Kilombero and Ulanga districts in the Moro-
goro region in south-east Tanzania. Kilombero and Ulanga dis-
tricts have a population of approximately 700,000 and around
6% of these are people living with HIV [22]. The main eco-
nomic activity is rice farming, with other sources of income
including fishing and mining [22]. The clinic has a cohort, KIU-
LARCO, as described previously [22,23]. Comprehensive data
are systematically captured in electronic medical records,
including demographic characteristics, ART use, laboratory
parameters, and clinical outcomes (since 2013; previously, lim-
ited data were captured on paper). In this study, we included
HIV-positive adults (aged ≥15 years) enrolled in 2005 to
2016 with follow-up through April 2017. We excluded transit
patients (those enrolled in other clinics who attended the
CDCI temporarily, usually for ART refills or a clinical consulta-
tion).
2.2 | Outcomes
Time was measured from cohort enrolment to outcomes of
death, transfer to another clinic, LTFU or in active care. LTFU
was defined as >60 days late for the next scheduled appoint-
ment [24], with visits scheduled every three months for those
on ART and every six months for those not yet on ART. Par-
ticipants could experience multiple LTFU episodes after
returning to care in the interim. Analyses were performed (a)
based on the first event observed for each participant during
follow-up (prospectively) and (b) accounting for recurrent
LTFU episodes, that is, participants could contribute multiple
LTFU episodes if they had transient interruptions in care, with
appropriate statistical methods to account for the correlations
caused by multiple events within the same participant. For
comparison purposes, we also performed analyses based on
the last event observed before database closure regardless of
previous event history (retrospectively), since this definition is
commonly used in the literature. The number of participants
was the same in all analyses.
2.3 | Covariates
We included covariates based on prior knowledge of poten-
tially being associated with LTFU. Baseline covariates were
sex, age, highest education level, occupation, marital status,
distance of residence from the clinic (estimated based on cen-
tre of ward of residence), partner HIV status, disclosure of
HIV status, pregnant, body mass index (BMI) [25], CD4 cell
count, HIV WHO stage, tuberculosis status (positive if positive
microscopy with acid-fast bacilli, positive Xpert MTB/RIF assay
(Cepheid, Sunnyvale, CA, USA) in sputum or other extra-pul-
monary sample, chest radiograph suggestive of tuberculosis
plus at least one symptom, physician diagnosis by ICD-10
code, or prescription of anti-tuberculosis medication), and
enrolment year [23]. Participants were considered on ART at
baseline if they initiated before or within 30 days of enrol-
ment. CD4 count, BMI, WHO stage and tuberculosis diagnosis
were those measurements closest to enrolment, provided
within 30 days. We incorporated time-dependent variables of
pregnancy (captured as binary variable, that is, pregnant or
not, during clinical visits) and time since ART initiation during
follow-up (not yet initiated, or initiated <6, 6 to <12, 12 to
<24 or ≥24 months ago). Guidelines for the management of
HIV/AIDS changed during the study: in 2005 to 2011, ART
was recommended for adults and adolescents with advanced
HIV/AIDS [26,27]; from 2012, those with WHO stage 3/4 and
CD4 count <350 cells/mm3 were eligible [28]; from 2015,
ART was available for those with CD4 count <500 cells/mm3
or co-infections such as tuberculosis [29].
2.4 | Statistical methods
2.4.1 | First and last event
In the presence of competing risk events (deaths and transfers),
we analysed time to first LTFU event using cumulative inci-
dence functions [30,31]. Cause-specific proportional hazards
models were used to assess factors associated with time to
first LTFU episode, with deaths and transfers censored [31,32].
We considered univariable and multivariable models, excluding
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education and occupation which were missing for >40% of par-
ticipants since they were not systematically captured until
2013. The same methods were used for the last event analysis.
We used multiple imputation with chained equations to
address missing baseline covariates, assuming data were miss-
ing at random [33]. In the imputations, we used predictive
mean matching for square-root-transformed BMI and CD4
count. We used logistic regression for the binary variables and
multinomial regression for the remaining categorical variables.
In addition to the baseline covariates, we included in the
imputations time since ART initiation over all follow-up,
whether ever pregnant during follow-up, an indicator for LTFU
for the first event, and the Nelson-Aalen estimator of the
baseline cumulative hazard [33,34]. We used 20 imputations,
based on the approximate fraction of missing information [35].
2.4.2 | Recurrent LTFU events
Participants often experienced multiple LTFU episodes; such
data require specialized approaches, because recurrent events
in the same participant are not independent [36,37]. We used
marginal means/rates models [38] and Prentice, Williams and
Peterson (PWP) [39] models. Marginal means/rates models
characterize the mean or rate of the event counting process
within individuals, without specifying a covariance structure
among recurrent events [12]. PWP models are extensions to
Cox models and correct the variance to account for within-
person correlations, with only individuals who have experi-
enced the (k-1)th event being at risk for the kth event [12,34].
We fitted PWP models with total time and gap time, with the
number of LTFU events truncated at four to avoid unstable
parameter estimates [12]. The PWP-total and -gap models dif-
fer in the risk intervals, with the former measuring time from
enrolment to the event, whereas the latter resets the clock
after each event and measures time between successive
events [12,34]. In all models, participants who died or trans-
ferred out were censored at the time of those events. Partici-
pants were not considered at risk during a LTFU episode, but
could re-enter the risk set if they returned to the clinic (simi-
larly following transfers). We also performed multiple imputa-
tion in a similar way, except that we included in addition LTFU
indicators and baseline cumulative hazards for up to the
fourth LTFU event [34].
Post-hoc, we assessed interactions between CD4 count and
enrolment year due to changes in treatment guidelines over
time. Analyses were performed using Stata [40].
2.5 | Ethical considerations
Ethical approval for the KIULARCO cohort has been obtained
from Ifakara Health Institute Review Board and the National
Health Research Committee of the National Institute of Medi-
cal Research of Tanzania. Written informed consent is sought
from all participants at registration at the CDCI; those who
refused consent were excluded.
3 | RESULTS
Of the 9251 participants enrolled in 2005 to 2016, we
excluded 795 aged <15 years, eight with missing birth date,
and 361 transit patients. We therefore included 8087 adults:
the majority were female (65%), aged ≥35 years (60%), had
no or only primary education (94%), were farmers (86%), were
married or cohabiting (55%), lived in Ifakara town (44%), had
a partner with unknown HIV status (67%), and had disclosed
their HIV status (68%; Table 1). 6% of women were pregnant.
Large proportions of participants had normal BMI (60%), had
CD4 count <200 cells/mm3 (47%), were WHO stage 1/2
(58%), did not have tuberculosis (93%), and did not initiate
ART within 30 days of enrolment (54%). HIV disclosure, BMI
and CD4 count had high missingness, mainly from earlier cal-
endar years. Excluding education and occupation (not captured
before 2013), 14% of baseline covariates were missing across
all participants.
3.1 | First event
Considering the time to the first event only, 5105 (63%) par-
ticipants were LTFU, while 516 (6%) died and 685 (8%) trans-
ferred out (Table 1). There were some differences in the
distribution of baseline characteristics by event, most notably
those living far from the clinic being more likely to be LTFU
or transfer out. Participants without partners or partners with
known HIV status, and those who initiated ART at baseline,
were more likely to remain in care. Participants classified as
underweight, with low CD4 count or high WHO stage were
more likely to die.
By the time of the first event, there had been 1001 preg-
nancies in 786 (15%) women. At the time of the first event,
most participants in active care or who had transferred out
had initiated ART (97% and 71% respectively), whereas smal-
ler proportions of those LTFU or who had died had initiated
ART (57% and 52% respectively).
The median follow-up time was 10 months (interquartile
range, IQR 5 to 26). The cumulative incidence of LTFU at one
year was 0.41 (95% confidence interval, CI 0.40 0.42) and
0.67 (0.66, 0.68) at five years (Figure 1). The cumulative inci-
dences of death and transfer were much lower, both at 0.06
(0.05, 0.06) at one year and remaining fairly steady thereafter.
LTFU was associated with being male, younger age, never
married, and living far from the clinic (Table 2). Underweight
participants and those with more advanced WHO stage had
increased risk of being LTFU, and there was some suggestion
that those with higher CD4 counts were less likely to be
LTFU. Factors which were associated with lower LTFU risk
were having an HIV-positive partner, having tuberculosis,
being pregnant, and longer time since ART initiation. Partici-
pants enrolled in 2005 to 2007 and 2013 to 2014 were at
lowest LTFU risk. There was no evidence of an interaction
between CD4 count and enrolment year (p = 0.30).
3.2 | Last event
Compared to the analysis based on the first event, under the
last event analysis the number of participants LTFU was much
smaller (3110, 38%), the number in active care was higher
(3203, 40%), and deaths and transfers out were broadly simi-
lar (811, 10% and 963, 12% respectively). Characteristic dis-
tributions by last event were similar to those by first event.
The cumulative incidence of LTFU at one year was 0.21 (95%
CI 0.20, 0.22) and 0.38 (0.37, 0.39) at five years (Figure S1).
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Table 1. Baseline characteristics by participant outcome (based on first event to occur during follow-up)
Characteristic In care Lost to follow-up Died Transferred to another clinic Total
Total, number (row %) 1781 (22%) 5105 (63%) 516 (6%) 685 (8%) 8087 (100%)
Sex
Male 555 (31%) 1841 (36%) 212 (41%) 240 (35%) 2848 (35%)
Female 1226 (69%) 3249 (64%) 304 (59%) 441 (65%) 5220 (65%)
Missing 0 15 (<1%) 0 4 (1%) 19 (<1%)
Age, years
15 to 24 115 (6%) 418 (8%) 29 (6%) 61 (9%) 623 (8%)
25 to 34 515 (29%) 1723 (34%) 153 (30%) 201 (29%) 2592 (32%)
35 to 44 627 (35%) 1751 (34%) 183 (35%) 244 (36%) 2805 (35%)
≥45 524 (29%) 1213 (24%) 151 (29%) 179 (26%) 2067 (26%)
Highest education level
None 155 (9%) 191 (8%) 13 (11%) 37 (11%) 396 (9%)
Primary school 1501 (85%) 2050 (86%) 103 (86%) 289 (84%) 3943 (85%)
Secondary school and above/other 116 (7%) 148 (6%) 4 (3%) 20 (6%) 288 (6%)
Missing 9 (1%) 2716 (53%) 396 (77%) 339 (49%) 3460 (43%)
Occupation
Farmer 1526 (86%) 2038 (85%) 105 (88%) 303 (88%) 3972 (86%)
Non-farmers 246 (14%) 351 (15%) 15 (13%) 43 (12%) 655 (14%)
Missing 9 (1%) 2716 (53%) 396 (77%) 339 (49%) 3460 (43%)
Marital status
Married/cohabiting 1042 (59%) 2671 (53%) 219 (46%) 395 (60%) 4327 (55%)
Never married 149 (8%) 842 (17%) 121 (25%) 73 (11%) 1185 (15%)
Separated/divorced/widowed 584 (33%) 1485 (30%) 141 (29%) 191 (29%) 2401 (30%)
Missing 6 (<1%) 107 (2%) 35 (7%) 26 (4%) 174 (2%)
Distance of residence from clinic, km
≤1 (i.e. resident in Ifakara town) 800 (46%) 1935 (43%) 240 (55%) 176 (31%) 3151 (44%)
2 to <50 608 (35%) 984 (22%) 63 (15%) 127 (23%) 1782 (25%)
50 to <80 98 (6%) 605 (13%) 62 (14%) 60 (11%) 825 (11%)
≥80 244 (14%) 960 (21%) 68 (16%) 196 (35%) 1468 (20%)
Missing 31 (2%) 621 (12%) 83 (16%) 126 (18%) 861 (11%)
Partner HIV sero-status
Positive 329 (20%) 636 (13%) 36 (7%) 116 (18%) 1117 (14%)
Negative 163 (10%) 338 (7%) 28 (6%) 48 (7%) 577 (7%)
Unknown 784 (47%) 3605 (73%) 385 (78%) 405 (62%) 5179 (67%)
Not applicable 389 (23%) 340 (7%) 47 (9%) 88 (13%) 864 (11%)
Missing 116 (7%) 186 (4%) 20 (4%) 28 (4%) 350 (4%)
HIV status disclosure
Not disclosed 410 (26%) 1486 (35%) 76 (23%) 138 (25%) 2110 (32%)
Disclosed 1176 (74%) 2736 (65%) 257 (77%) 415 (75%) 4584 (68%)
Missing 195 (11%) 883 (18%) 183 (35%) 132 (19%) 1393 (17%)
Pregnanta
No 1128 (92%) 3066 (94%) 297 (98%) 417 (95%) 4908 (94%)
Yes 98 (8%) 183 (6%) 7 (2%) 24 (5%) 312 (6%)
BMI, kg/m2b
Underweight (<18.5) 322 (20%) 1075 (27%) 154 (42%) 154 (28%) 1705 (26%)
Normal (18.5 to <25) 984 (62%) 2397 (60%) 186 (51%) 335 (60%) 3902 (60%)
Overweight (≥25) 292 (18%) 546 (14%) 23 (6%) 66 (12%) 927 (14%)
Missing 85 (5%) 904 (18%) 146 (29%) 106 (16%) 1241 (16%)
CD4 count, cells/mm3
<100 335 (25%) 741 (25%) 133 (53%) 126 (29%) 1335 (27%)
100 to 199 290 (21%) 554 (19%) 38 (15%) 104 (24%) 986 (20%)
200 to 349 352 (26%) 609 (21%) 34 (14%) 97 (22%) 1092 (22%)
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The corresponding results for death were 0.06 (0.06, 0.07)
and 0.10 (0.09, 0.10), and for transfers 0.05 (0.04, 0.05) and
0.12 (0.11, 0.13).
The factors associated with LTFU were broadly similar to
the first event analysis, except that there was no longer as
strong a relationship with age, disclosure of HIV status was
associated with lower LTFU risk, there was a stronger trend
towards higher LTFU risk with lower BMI, and pregnancy was
associated with higher risk of LTFU (Table 2). In addition, par-
ticipants enrolled in 2010 to 2012 and particularly 2015 to
2016 were at higher risk of LTFU versus 2008 to 2009.
3.3 | Recurrent LTFU events
There were 8140 LTFU episodes, following which there were
2483 (31%) returns to care after a median of three months
following the last scheduled appointment (IQR 2 to 6). Overall,
5293 (65%) participants had at least one LTFU episode, with
a median of one episode/participant (Figure 2). There were
1387 transfers out among 1360 (17%) participants, 811
(10%) died and 1781 (22%) remained in care throughout.
Among the 5105 participants whose first event was LTFU,
2583 (51%) returned to care. Participant characteristics were
broadly similar among those who did versus did not return to
care, except that those who did not return tended to be more
likely to have never married, be underweight, have more
advanced WHO stage, have lower CD4 count, and have
shorter time from enrolment to LTFU (Table S1). Over all fol-
low-up, 6187 (77%) participants initiated ART and there were
1351 pregnancies in 998 (19%) women.
Associations between LTFU and covariates in the recurrent
events models were broadly similar to the first LTFU event
analysis, except that there was no longer evidence of an
Table 1. (Continued)
Characteristic In care Lost to follow-up Died Transferred to another clinic Total
350 to 499 190 (14%) 429 (15%) 29 (12%) 54 (12%) 702 (14%)
≥500 191 (14%) 585 (20%) 17 (7%) 58 (13%) 851 (17%)
Missing 423 (24%) 2187 (43%) 265 (51%) 246 (36%) 3121 (39%)
WHO stage
Stage 1 693 (41%) 1988 (40%) 79 (16%) 229 (34%) 2989 (38%)
Stage 2 364 (22%) 1019 (21%) 71 (14%) 126 (19%) 1580 (20%)
Stage 3 471 (28%) 1299 (26%) 166 (34%) 215 (32%) 2151 (28%)
Stage 4 156 (9%) 618 (13%) 175 (36%) 99 (15%) 1048 (13%)
Missing 97 (5%) 181 (4%) 25 (5%) 16 (2%) 319 (4%)
Tuberculosis status
No 1488 (90%) 4747 (95%) 474 (92%) 603 (90%) 7312 (93%)
Yes 164 (10%) 243 (5%) 41 (8%) 65 (10%) 513 (7%)
Missing 129 (7%) 115 (2%) 1 (<1%) 17 (2%) 262 (3%)
ART status (within 30 days of enrolment)
Not yet initiated ART 530 (30%) 3172 (62%) 333 (65%) 349 (51%) 4384 (54%)
Initiated ART 1251 (70%) 1933 (38%) 183 (35%) 336 (49%) 3703 (46%)
Year of registration
2005 to 2007 121 (7%) 1312 (26%) 224 (43%) 143 (21%) 1800 (22%)
2008 to 2009 208 (12%) 1776 (35%) 131 (25%) 176 (26%) 2291 (28%)
2010 to 2012 344 (19%) 1069 (21%) 58 (11%) 116 (17%) 1587 (20%)
2013 to 2014 417 (23%) 461 (9%) 22 (4%) 93 (14%) 993 (12%)
2015 to 2016 691 (39%) 487 (10%) 81 (16%) 157 (23%) 1416 (18%)
Results are number and column % of those with non-missing data, unless otherwise indicated; missing data rows are number and column %. Miss-
ing data for sex, education, occupation and marital status happened before 2013. Missing data for distance, partner HIV sero-status, HIV disclo-
sure, BMI, CD4 count and WHO stage occurred mainly before 2013. Tuberculosis status was most frequently missing from 2013 onwards. ART,
antiretroviral therapy; BMI, body mass index.
aPercentages are of number of women;; bExcluding pregnant women.
Figure 1. Cumulative incidence function for the first event. LTFU,
lost to follow-up.
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Table 2. Factors associated with lost to follow-up
Characteristic
Cause-specific
proportional hazard
model; first event
HR (95% CI)
Cause-specific
proportional hazard
model; last event
HR (95% CI)
Marginal
means/rates model;
recurrent events
RR (95% CI)
PWP-total
model; recurrent
events
HR (95% CI)
PWP-gap model;
recurrent
events
HR (95% CI)
Sex
Male versus female 1.24 (1.16, 1.32) 1.27 (1.17, 1.37) 1.17 (1.11, 1.23) 1.18 (1.12, 1.25) 1.23 (1.17, 1.29)
Age, years
15 to 24 1.20 (1.07, 1.34) 1.10 (0.96, 1.27) 1.15 (1.04, 1.27) 1.15 (1.05, 1.26) 1.18 (1.08, 1.29)
25 to 34 1.12 (1.04, 1.20) 1.08 (0.99, 1.18) 1.06 (1.00, 1.13) 1.07 (1.01, 1.13) 1.09 (1.03, 1.15)
35 to 44 Ref Ref Ref Ref Ref
≥45 0.92 (0.86, 0.99) 0.97 (0.88, 1.06) 0.96 (0.89, 1.02) 0.96 (0.90, 1.02) 0.94 (0.89, 1.00)
Marital status
Married/cohabiting Ref Ref Ref Ref Ref
Never married 1.23 (1.12, 1.35) 1.65 (1.49, 1.83) 1.28 (1.19, 1.38) 1.31 (1.21, 1.41) 1.37 (1.28, 1.47)
Separated/divorced/widowed 0.94 (0.88, 1.01) 0.89 (0.81, 0.98) 0.97 (0.92, 1.03) 0.97 (0.92, 1.03) 0.97 (0.92, 1.03)
Distance of residence from clinic, km
≤1 (i.e. resident in Ifakara town) Ref Ref Ref Ref Ref
2 to <50 0.85 (0.79, 0.92) 0.86 (0.78, 0.95) 0.92 (0.86, 0.98) 0.91 (0.86, 0.97) 0.88 (0.83, 0.93)
50 to <80 1.22 (1.11, 1.35) 1.68 (1.51, 1.88) 1.36 (1.26, 1.47) 1.34 (1.24, 1.44) 1.34 (1.24, 1.45)
≥80 1.26 (1.16, 1.37) 1.31 (1.18, 1.45) 1.30 (1.22, 1.39) 1.31 (1.23, 1.40) 1.42 (1.33, 1.51)
Partner HIV sero-status
Positive 0.82 (0.74, 0.90) 0.78 (0.69, 0.89) 0.86 (0.79, 0.93) 0.87 (0.80, 0.94) 0.85 (0.79, 0.91)
Negative 0.92 (0.82, 1.04) 0.97 (0.84, 1.13) 1.00 (0.90, 1.11) 0.99 (0.90, 1.08) 0.96 (0.87, 1.06)
Unknown Ref Ref Ref Ref Ref
Not applicable 0.93 (0.81, 1.08) 0.89 (0.75, 1.06) 0.99 (0.87, 1.13) 0.99 (0.88, 1.11) 0.99 (0.88, 1.11)
HIV disclosure status
Disclosed versus not disclosed 0.96 (0.89, 1.04) 0.90 (0.82, 0.98) 0.95 (0.89, 1.01) 0.95 (0.89, 1.00) 0.98 (0.93, 1.04)
BMI, kg/m2
Underweight (<18.5) 1.15 (1.07, 1.25) 1.27 (1.16, 1.39) 1.07 (1.00, 1.13) 1.07 (1.01, 1.14) 1.10 (1.04, 1.17)
Normal (18.5 to <25) Ref Ref Ref Ref Ref
Overweight (≥25) 0.93 (0.84, 1.02) 0.82 (0.72, 0.93) 0.94 (0.86, 1.02) 0.95 (0.87, 1.03) 0.94 (0.87, 1.01)
CD4 count, cells/mm3
<100 Ref Ref Ref Ref Ref
100 to 199 1.00 (0.88, 1.13) 0.92 (0.81, 1.04) 0.99 (0.88, 1.11) 1.00 (0.90, 1.12) 1.02 (0.89, 1.17)
200 to 349 1.00 (0.88, 1.13) 0.95 (0.83, 1.08) 1.00 (0.91, 1.09) 1.01 (0.93, 1.11) 1.00 (0.90, 1.12)
350 to 499 0.86 (0.74, 0.99) 0.84 (0.72, 0.98) 0.96 (0.85, 1.08) 0.96 (0.84, 1.09) 0.93 (0.84, 1.04)
≥500 0.86 (0.76, 0.99) 0.88 (0.76, 1.03) 1.01 (0.91, 1.12) 0.97 (0.86, 1.09) 0.92 (0.83, 1.02)
WHO stage
Stage 1 Ref Ref Ref Ref Ref
Stage 2 0.97 (0.90, 1.05) 0.92 (0.83, 1.02) 0.93 (0.87, 1.00) 0.92 (0.86, 0.98) 0.95 (0.89, 1.01)
Stage 3 1.16 (1.07, 1.25) 1.17 (1.05, 1.29) 1.08 (1.00, 1.15) 1.07 (1.00, 1.15) 1.14 (1.07, 1.21)
Stage 4 1.34 (1.20, 1.49) 1.61 (1.43, 1.82) 1.26 (1.15, 1.37) 1.28 (1.18, 1.39) 1.35 (1.24, 1.46)
Tuberculosis status
Positive versus negative 0.86 (0.75, 0.99) 0.80 (0.68, 0.95) 0.86 (0.76, 0.97) 0.84 (0.75, 0.95) 0.87 (0.78, 0.98)
Time since ART initiation, months
Not yet initiated ART Ref Ref Ref Ref Ref
0 to <6 0.81 (0.75, 0.89) 0.61 (0.55, 0.68) 0.60 (0.56, 0.65) 0.55 (0.51, 0.59) 0.55 (0.51, 0.60)
6 to <12 0.26 (0.24, 0.29) 0.32 (0.27, 0.37) 0.67 (0.62, 0.73) 0.60 (0.55, 0.66) 0.54 (0.49, 0.59)
12 to <24 0.23 (0.20, 0.25) 0.47 (0.40, 0.55) 0.60 (0.56, 0.65) 0.57 (0.52, 0.61) 0.37 (0.34, 0.40)
≥24 0.13 (0.12, 0.15) 0.36 (0.31, 0.42) 0.50 (0.46, 0.55) 0.47 (0.43, 0.51) 0.32 (0.30, 0.35)
Pregnant
Yes versus no 0.70 (0.58, 0.84) 1.54 (1.20, 1.98) 1.27 (1.08, 1.49) 1.25 (1.07, 1.46) 1.69 (1.44, 1.98)
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association with CD4 count, and pregnancy was associated
with higher risk of LTFU (Table 2). In addition, there were dif-
ferences in the pattern of recurrent LTFU by enrolment year
under the marginal means/rates and PWP-total models, with
those enrolled in later years at higher risk of recurrent LTFU.
Under the PWP-gap model, the relationship between recur-
rent LTFU and enrolment year was broadly similar to that in
the first event analysis. There was no evidence of interactions
between CD4 count and enrolment year (p = 0.97, 0.97 and
0.42 for the marginal means/rates, PWP-total and PWP-gap
models respectively).
4 | DISCUSSION
In this large, rural cohort of adults living with HIV, the proba-
bility of LTFU was high when analysed prospectively, at 41%
by one year after enrolment and stabilizing around 70% by
five years. However, transient interruptions in care were
common, with a third of LTFU episodes followed by a return
to care, and overall two-thirds of participants experiencing at
least one LTFU episode. Considering the last event before
database closure, the probability of LTFU at one year was
roughly half, at 21%, similar to a previous study in Tanzania
[13]. The large difference between cumulative incidences
based on the first and last event definitions has been noted
by others, with the last event approach tending to overesti-
mate LTFU in later years [11]. While the different approaches
represent different research questions, our results illustrate
the importance of clear definitions and exercising caution in
comparing estimates across studies. Studies assessing LTFU
predictors should use a prospective definition of LTFU, and
take into account period of enrolment [11]. Retrospective out-
come definitions may be appropriate in other situations, for
example in mortality assessment, since it allows for the inclu-
sion of more follow-up time [11].
Participant characteristics associated with LTFU can be
used to identify higher risk individuals for tracing after non-
attendance and to help design appropriate interventions to
improve retention in care. Our findings are in line with the lit-
erature: young people are more difficult to retain in long-term
care because they are more likely to be mobile while search-
ing for employment opportunities [41,42]. Participants who
were never married and those without HIV-positive partners
were at higher LTFU risk, which may be due to a lack of fam-
ily support [43,44] and/or stigma [45]. Furthermore, the high
incidence of LTFU during the first year may be linked to
stigma [46], suggesting that counselling and support following
HIV diagnosis may help patients to accept their diagnosis and
increase motivation to continue with life-long HIV treatment
[46]. A substantial proportion of participants in our study lived
far from the clinic (31% >50 km), and this was associated with
a higher LTFU risk. Accessibility problems such as lack of
transport, cost or distance have previously been identified as
barriers to clinic attendance [43,44]. Potential interventions
could include longer ART refills for those stable on treatment
as recently recommended by the Tanzanian government
[47,48], decentralization of care to local health clinics, or alter-
native ART delivery models such as to the home or through
the community [49]. Participants with low BMI or advanced
WHO stage were more likely to become LTFU, probably
Table 2. (Continued)
Characteristic
Cause-specific
proportional hazard
model; first event
HR (95% CI)
Cause-specific
proportional hazard
model; last event
HR (95% CI)
Marginal
means/rates model;
recurrent events
RR (95% CI)
PWP-total
model; recurrent
events
HR (95% CI)
PWP-gap model;
recurrent
events
HR (95% CI)
Year of registration
2005 to 2007 0.53 (0.49, 0.58) 0.71 (0.64, 0.78) 0.74 (0.68, 0.80) 0.79 (0.74, 0.86) 0.69 (0.65, 0.74)
2008 to 2009 Ref Ref Ref Ref Ref
2010 to 2012 0.96 (0.89, 1.04) 1.25 (1.12, 1.38) 1.32 (1.22, 1.44) 1.38 (1.28, 1.50) 0.91 (0.85, 0.97)
2013 to 2014 0.59 (0.52, 0.66) 0.76 (0.64, 0.89) 1.32 (1.16, 1.51) 1.88 (1.65, 2.14) 0.60 (0.54, 0.66)
2015 to 2016 0.83 (0.73, 0.94) 2.00 (1.73, 2.32) 2.18 (1.88, 2.53) 3.31 (2.82, 3.87) 0.94 (0.85, 1.05)
Results are from models with multiple imputation for missing baseline covariates. All variables are defined at baseline, except time since ART initi-
ation and pregnancy which are time-dependent. ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; HR, hazard ratio; RR,
rate ratio.
Figure 2. Distribution of lost to follow-up events.
Participants who remained in care, died or transferred out without
ever being lost to follow-up are included as having zero lost to follow-
up events. For the Prentice, Williams and Peterson (PWP) models, the
number of events was truncated at four.
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indicating disease progression with unreported deaths [50].
Furthermore, being sick may directly impair clinic attendance
[44]. Participants with tuberculosis were less likely to become
LTFU, probably related to their existing engagement in care
for another chronic condition. The high incidence of LTFU
among ART-na€ıve participants in our cohort has been
observed in previous studies, albeit using different LTFU defi-
nitions [41,43,51]. Historically, ART was not initiated until clini-
cally indicated, and therefore individuals did not need to
attend the clinic to collect refills [26–29]. With recent changes
in guidelines to recommend treatment for all, this inherent
bias may be ameliorated [52]. Regardless, two-thirds of LTFU
episodes occurred in participants on ART, likely resulting in
suboptimal adherence and therefore risk of poorer individual
outcomes [53,54] and onwards sexual transmission [55,56].
However, such participants may have sought drug refills from
another clinic without our knowledge. Regardless of ART sta-
tus, participants who were LTFU from our clinic may have “si-
lently” transferred care to another clinic [57] or died without
notification to the clinic [50], particularly given that those par-
ticipants who were LTFU and did not return to the clinic had
poorer clinical prognoses than those who returned. The
national electronic database of HIV care and treatment cen-
tres does not currently allow extraction of data from other
centres, which would help to trace patients LTFU. Future stud-
ies could investigate the impact of silent transfers and unre-
ported deaths through such linkage with other clinics and/or
tracing in the community.
The models for assessing first and recurrent LTFU events
have different underlying assumptions, estimate different
parameters, and hence have different interpretations. Despite
these differences, we observed comparable results across the
models, suggesting that in this population the factors associ-
ated with first, last and recurrent LTFU were broadly similar.
One exception was pregnancy which was associated with
lower LTFU risk in the first event analysis, but higher risk in
the recurrent and last event models, in line with previous
studies [20,21]. This highlights the higher risk of recurrent
LTFU among pregnant women who have already struggled
with attendance. The second exception was CD4 count: higher
baseline levels were associated with lower LTFU in the first
event analysis, but not in the recurrent or last event analyses,
likely due to unreported deaths in the short-term among par-
ticipants with low baseline values. Lastly, there was a trend
towards higher LTFU risk in later enrolment years under the
last event analysis, but this is biased due to transient interrup-
tions in care [11]. We observed similar trends when modelling
recurrent LTFU events with marginal means/rates and PWP-
total models, but under the PWP-gap model and for the first
event analysis we observed somewhat lower LTFU risks in
later years. With changes in HIV guidelines, which can influ-
ence HIV care and treatment service delivery and hence mod-
ify participants’ behaviour, improvement of data collection
tools in our clinic, and increased awareness about HIV in the
community, we would anticipate the incidence of LTFU to
decrease over time. Further research is required to determine
whether the marginal means/rates and PWP-total models may
be susceptible to the same biases as the last event analyses.
Some bias may remain in the estimates from the recurrent
event models if long periods are permitted before declaring a
participant LTFU [11]; we chose a delay of 60 days based on
the recommendations of previous studies [10,24]. Further-
more, participants were not at risk for further events during a
LTFU episode (which may have long duration). An alternative
approach would be to use multi-state models, which explicitly
model the probabilities of transitioning between different
states, for example LTFU, under care, transfer to other clinics
or death [12].
Strengths of our study include the long cohort follow-up,
the standardized data capture system, and use of multiple
imputation to address missing baseline covariates. Further-
more, we appropriately addressed recurrent LTFU episodes
which are often neglected or incompletely described in many
studies. The study has several limitations. Pregnancy was
recorded only as a binary status at each visit; capture of deliv-
ery dates would enable us to better examine the pregnancy
and postpartum periods. We included as a covariate the time
since ART initiation, with the assumption that once individuals
initiate ART then they remain on it. The multiple imputation
methods assume that data were missing at random; we cannot
assess this assumption in the data but we increased the plau-
sibility of our findings by incorporating a broad range of
covariates [35]. Education and occupation were not collected
pre-2013 and therefore were not included in the multivariable
analyses, but may mediate the effect of some of the other
covariates modelled. We considered it important to apply a
consistent LTFU definition throughout the cohort, but visits
were scheduled approximately monthly pre-2012 and for
pregnant women, therefore we may have underestimated
LTFU incidence in some participants.
5 | CONCLUSIONS
In this cohort, LTFU episodes were common, potentially jeop-
ardizing the success of ART for individual prognosis and treat-
ment as prevention [2,3]. Optimization of retention in care
must be prioritized if we are to improve the long-term out-
comes of HIV-positive persons and reach the third of the
UNAIDS 90-90-90 targets to curb the HIV epidemic [2]. We
have identified important socio-demographic and clinical char-
acteristics which may be used to target prompt tracing efforts
or inform the design of interventions, such as longer ART
refills or home/community ART delivery for stable patients liv-
ing far from the clinic, and connecting those without sufficient
social support with treatment supporters. Furthermore, we
have demonstrated the effects of transient interruptions in
care on the incidence of and risk factors for LTFU, and the
importance of clearly describing and appropriately accounting
for such episodes. We recommend using a prospective defini-
tion of LTFU combined with recurrent event analyses in
cohorts where repeated interruptions in care are common.
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